Teva price target raised to $25 from $22 at Barclays

Oct 23, 2024 · Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...

CouponFollow Extension

$25
OFF

Teva Price Target Raised To $25 From $22 At Barclays

2 weeks from now

businessinsider.com

26%
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · TEVA. 1.26%. Barclays has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Gets A Buy From Barclays

2 weeks from now

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$25.00
OFF

Barclays Reaffirms Their Buy Rating On Teva Pharmaceutical (TEVA)

2 weeks from now

Nov 6, 2024 · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$19.67
OFF

Teva Pharmaceutical Industries (TEVA) Stock Forecast & Price Target

2 weeks from now

1 day ago · Consensus Price Target. According to the 9 analysts' twelve-month price targets for Teva Pharmaceutical Industries, the average price target is $19.67. The highest price target …

marketbeat.com

$25.00
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · Barclays (LON: BARC) has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Receives A Buy From Barclays

2 weeks from now

Oct 23, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares …

businessinsider.com

$13
OFF

Barclays Upgrades Teva To Overweight, Lifts Price Target To $13

2 weeks from now

Apr 6, 2022 · Teva Pharmaceutical received a rating upgrade from Barclays based on the generic drug manufacturer’s upward revision of revenue forecasts for Humira biosimilar. ... Home > …

tradersasset.com

28%
OFF

Barclays Sets A Price Target For Teva Pharmaceutical Industries Ltd ...

2 weeks from now

Jun 6, 2024 · This new target suggests a potential upside of about 26.28%, indicating a bullish outlook on the stock. Teva, a global pharmaceutical company, is known for its wide range of …

cweb.com

$17.00
OFF

Barclays Sticks To Its Buy Rating For Teva Pharmaceutical (TEVA)

2 weeks from now

Feb 5, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $17.00. The company’s shares …

businessinsider.com

FAQs about Teva price target raised to $25 from $22 at Barclays Coupon?

What is the price target for Teva?

The highest price target for TEVA is $26.00, while the lowest price target for TEVA is $11.00. The average price target represents a forecasted upside of 1.55% from the current price of $18.60. Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. ...

Should you buy Teva Pharmaceutical (Teva)?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. In a report released on October 16, UBS also maintained a Buy rating on the stock with a $26.00 price target. ...

What is the forecast for Teva Pharmaceutical Industries stock?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Teva Pharmaceutical Industries is $18.89, with a high forecast of $26.00 and a low forecast of $11.00. Should I buy or sell Teva Pharmaceutical Industries stock right now? ...

Is Teva Pharmaceutical Industries a good stock to buy?

According to analysts, Teva Pharmaceutical Industries's stock has a predicted upside of 23.89% based on their 12-month stock forecasts. Has Teva Pharmaceutical Industries been upgraded by Wall Street analysts recently? Over the previous 90 days, Teva Pharmaceutical Industries's stock had 1 upgrade by analysts. ...

Do Wall Street analysts like Teva Pharmaceutical Industries?

Do Wall Street analysts like Teva Pharmaceutical Industries more than its competitors? Analysts like Teva Pharmaceutical Industries more than other "medical" companies. The consensus rating score for Teva Pharmaceutical Industries is 2.78 while the average consensus rating score for "medical" companies is 2.76. ...

Should you buy Prasad pharmaceutical (Teva)?

According to TipRanks, Prasad has an average return of 3.0% and a 46.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. ...